Related Experiment Video

Updated: Jun 20, 2026

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
08:54

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

Published on: February 14, 2018

[Antifungal combination therapy in invasive fungal infections]

J Gellen-Dautremer1, F Lanternier, E Dannaoui

  • 1Service de médecine interne, hôpital Beaujon, Clichy, France.

La Revue De Medecine Interne
|September 22, 2009
PubMed

Insights

Combination antifungal therapies show promise for severe invasive fungal infections like candidiasis, aspergillosis, and cryptococcosis, particularly in immunocompromised patients. Further randomized studies are needed to confirm efficacy and optimize treatment strategies.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pharmacology

Context:

  • Invasive fungal infections (IFIs) pose significant threats to immunocompromised individuals, leading to high morbidity and mortality.
  • Current treatment guidelines primarily recommend single antifungal agents, with exceptions for cryptococcosis.
  • The severe outcomes associated with IFIs necessitate exploration of combination antifungal therapies.

Purpose:

  • To review the current evidence and potential benefits of combining antifungal agents for treating invasive fungal infections.
  • To highlight specific combination therapies showing promise in candidiasis, aspergillosis, and cryptococcosis.
  • To identify the need for further randomized controlled trials to validate these combination approaches.

Summary:

  • Combination therapy, such as amphotericin B plus flucytosine for cryptococcal meningitis, is validated in human studies.
  • Experimental data suggest non-antagonistic effects of fluconazole plus amphotericin B in candidiasis.
  • Combinations like caspofungin with polyenes or azoles may benefit invasive aspergillosis, with ongoing trials for anidulafungin plus voriconazole.

Impact:

  • Combination antifungal therapy may offer improved outcomes for severe IFIs in high-risk patient populations.
  • Evidence supports further investigation into optimized combination strategies to combat life-threatening fungal infections.
  • Future research, including randomized trials, is crucial for establishing definitive guidelines on antifungal combinations.

More Related Videos

Quantifying the Antifungal Activity of Peptides Against Candida albicans06:45

Quantifying the Antifungal Activity of Peptides Against Candida albicans

Published on: January 13, 2023

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...